Compugen (CGEN) awards CEO Ophir Eran 200,000 share options

Rhea-AI Filing Summary

Compugen Ltd President and CEO Ophir Eran received a grant of 200000.0000 share options for ordinary shares on 2026-07-29. The options carry a $2.2600 exercise price and expire on 2036-07-29. They vest 25% on September 30, 2027, then in 12 equal quarterly installments, subject to continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ophir Eran

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Share Option (right to buy) F1	200,000	$0.00	$0.00

Holdings After Transaction: Share Option (right to buy) — 200,000 shares (Direct)

Footnotes (1)

1. F1. This option vests 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

Key Figures

Options granted: 200000.0000 options Exercise price: $2.2600 per share Expiration date: 2036-07-29 +2 more

5 metrics

Options granted 200000.0000 options Share Option (right to buy) granted to President and CEO Ophir Eran on 2026-07-29

Exercise price $2.2600 per share Conversion or exercise price for the granted share options

Expiration date 2036-07-29 Expiration date of the CEO share option grant

Initial vesting percentage 25% Portion of the option that vests on September 30, 2027

Remaining vesting installments 12 equal quarterly installments Remaining 75% of the option vests in 12 equal quarterly installments after initial vesting

Key Terms

Share Option (right to buy), vesting, Ordinary Shares

3 terms

Share Option (right to buy) financial

"Security title is "Share Option (right to buy)" for this derivative grant"

vesting financial

"This option vests 25% on September 30, 2027, and the remainder vests thereafter"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Ordinary Shares financial

"Underlying security title is "Ordinary Shares" for the option grant"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/30/2026 - 04:10 PM Accepted by SEC EDGAR 07/30/2026 - 04:10 PM Learn about SEC filing dates

FAQ

What stock option grant did Compugen (CGEN) report for CEO Ophir Eran?

Compugen reported that CEO Ophir Eran received a grant of 200000.0000 share options for ordinary shares on 2026-07-29. The options were awarded at a grant price of $0.0000 per option and provide the right to buy the company’s ordinary shares at a set exercise price.

What is the exercise price and expiration of Ophir Eran's new Compugen (CGEN) options?

The granted options have a $2.2600 exercise price per ordinary share and expire on 2036-07-29. They cover 200000.0000 underlying ordinary shares, giving the CEO the right to purchase those shares at the fixed exercise price before the expiration date.

How do CEO Ophir Eran's Compugen (CGEN) options vest?

The options vest 25% on September 30, 2027, with the remaining 75% vesting in 12 equal quarterly installments. Vesting is conditioned on Ophir Eran continuing to serve Compugen, tying the economic benefit of the grant to his ongoing leadership over several years.

How many Compugen (CGEN) ordinary shares underlie the CEO's new option grant?

The option grant covers 200000.0000 underlying ordinary shares. Each option represents the right to purchase one ordinary share, so full exercise of the grant would allow CEO Ophir Eran to acquire up to 200000.0000 Compugen ordinary shares, subject to vesting and expiration terms.

Is the 200000.0000 option award to Compugen (CGEN)'s CEO a market purchase?

No, it is a grant/award acquisition, not a market purchase. The transaction price per option is reported as $0.0000, with a separate $2.2600 exercise price that would apply if Ophir Eran later chooses to exercise the vested options for ordinary shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ophir Eran

(Last) (First) (Middle)

C/O COMPUGEN LTD.

26 HAROKMIM STREET

(Street)

HOLON 5885849

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
COMPUGEN LTD [ CGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol
[CGEN]

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$2.26	07/29/2026		A		200,000		(1)	07/29/2036	Ordinary Shares	200,000	$0	200,000	D

Explanation of Responses:

1. This option vests 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

	/s/ Eran Ophir	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)